Horizon Therapeutics (HZNP) intends to offer $500M aggregate principal amount of senior notes due 2027.
Horizon expects to use the net proceeds, together with ~$64M in cash on hand, to redeem $525M of its outstanding debt as well as to pay the related premiums, and fees and expenses, excluding accrued interest, associated with the redemption.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.